{"id":"nva237","_chembl":{"chemblId":"CHEMBL1201335","moleculeType":"Small molecule","molecularWeight":"318.44"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NVA237","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:14:40.220479+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:14:46.389748+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NVA237","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:14:48.120304+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201335/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:14:48.894325+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:57:56.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:14:50.680956+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT05222529","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-29","conditions":"Asthma","enrollment":42},{"nctId":"NCT03379233","phase":"PHASE3","title":"A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":7},{"nctId":"NCT01613690","phase":"PHASE1","title":"Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Renal Impairment","enrollment":48},{"nctId":"NCT02371629","phase":"PHASE4","title":"A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":776},{"nctId":"NCT01985334","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-14","conditions":"COPD","enrollment":4389},{"nctId":"NCT03137784","phase":"PHASE2, PHASE3","title":"Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-04","conditions":"Asthma","enrollment":148},{"nctId":"NCT01757015","phase":"PHASE3","title":"Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT00856193","phase":"PHASE2","title":"A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33},{"nctId":"NCT01837927","phase":"PHASE3","title":"Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT01727141","phase":"PHASE3","title":"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1042},{"nctId":"NCT01697696","phase":"PHASE3","title":"Long Term Safety Study of NVA237 vs QAB149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":511},{"nctId":"NCT01699685","phase":"PHASE3","title":"Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease: COPD","enrollment":79},{"nctId":"NCT01712516","phase":"PHASE3","title":"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1001},{"nctId":"NCT02127697","phase":"PHASE3","title":"Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03","conditions":"Asthma","enrollment":""},{"nctId":"NCT01119950","phase":"PHASE2","title":"Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":388},{"nctId":"NCT01709903","phase":"PHASE3","title":"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":744},{"nctId":"NCT01715298","phase":"PHASE3","title":"NVA237 BID Versus Placebo Twelve-week Efficacy Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":432},{"nctId":"NCT01709864","phase":"PHASE3","title":"NVA237 Versus Placebo 12-week Efficacy Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":440},{"nctId":"NCT01513460","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":773},{"nctId":"NCT01922271","phase":"PHASE4","title":"Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":152},{"nctId":"NCT01604278","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":449},{"nctId":"NCT01566604","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":460},{"nctId":"NCT01613326","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":657},{"nctId":"NCT01529632","phase":"PHASE3","title":"Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":193},{"nctId":"NCT01285492","phase":"PHASE3","title":"Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":160},{"nctId":"NCT01120691","phase":"PHASE3","title":"Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2224},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT01315249","phase":"PHASE3","title":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":523},{"nctId":"NCT01119937","phase":"PHASE3","title":"Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":211},{"nctId":"NCT00929110","phase":"PHASE3","title":"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1066},{"nctId":"NCT00510510","phase":"PHASE2","title":"Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":281},{"nctId":"NCT00501852","phase":"PHASE2","title":"Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":83},{"nctId":"NCT01154127","phase":"PHASE3","title":"Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT01005901","phase":"PHASE3","title":"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1324},{"nctId":"NCT00545311","phase":"PHASE1","title":"Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":33,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":13,"reaction":"PNEUMONIA"},{"count":3,"reaction":"CONCOMITANT DISEASE PROGRESSION"},{"count":3,"reaction":"COUGH"},{"count":2,"reaction":"ACUTE MYOCARDIAL INFARCTION"},{"count":2,"reaction":"ARTERIAL OCCLUSIVE DISEASE"},{"count":2,"reaction":"CARDIO-RESPIRATORY ARREST"},{"count":2,"reaction":"DISEASE PROGRESSION"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"HYPERTENSION"}],"crossReferences":{"chemblId":"CHEMBL1201335"},"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glycopyrronioum bromide"],"phase":"marketed","status":"active","brandName":"NVA237","genericName":"NVA237","companyName":"Novartis Pharmaceuticals","companyId":"novartis-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:14:50.680956+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}